VarmX
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2025-06-01attributed |
| Founded | 2010 |
| Headquarters | Leiden, Netherlands |
| Industry | biotech |
| Stage | unknown |
| Website | varmx.com |
VarmX develops VMX-C001, a universal reversal agent that restores blood coagulation in patients on Factor Xa direct oral anticoagulants. It serves emergency-medicine teams treating severe bleeding and surgeons operating on anticoagulated patients. Its mechanism-agnostic restoration of clotting works across all FXa-DOACs, where the only approved competitor (Andexxa) targets only apixaban and rivaroxaban.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | grant | $2.7M | undisclosed |
Detected tech stack
Cloudflare, reCAPTCHA, Google Analytics, Google Tag Manager, Font Awesome, jQuery CDN, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 4.0.9, DoubleClick Floodlight, Cloudflare Bot Management, Contact Form 7 6.1.6
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | varmx.com, read 2026-05-08 |
| Description | self-reported | varmx.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.